Proceeds used for phase 1 clinical trials, general corporate purposes
By Devika Patel
Knoxville, Tenn., Sept. 18 - Five Prime Therapeutics, Inc. said it priced its $62.4 million initial public offering of stock with a $9.36 million greenshoe. The deal was announced on July 26.
The company will sell 4.8 million common shares at $13.00 per share.
Jefferies LLC, BMO Capital Markets and Wells Fargo Securities, LLC are the joint bookrunning managers.
Settlement is expected on Sept. 23.
Proceeds will be used for a phase 1 clinical trial of FPA008, a phase 1 clinical trial of FPA144, working capital and general corporate purposes.
The clinical-stage biotechnology company is based in South San Francisco, Calif. The company intends to list its common stock on the Nasdaq exchange under the symbol "FPRX."
| Issuer: | Five Prime Therapeutics, Inc.
|
| Issue: | Common stock
|
| Amount: | $62.4 million
|
| Greenshoe: | $9.36 million
|
| Shares: | 4.8 million
|
| Price: | $13.00
|
| Warrants: | No
|
| Bookrunners: | Jefferies LLC, BMO Capital Markets and Wells Fargo Securities, LLC
|
| Co-manager: | Guggenheim Securities, LLC
|
| Announcement date: | July 26
|
| Pricing date: | Sept. 18
|
| Settlement date: | Sept. 23
|
| Stock exchange: | Nasdaq: FPRX
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
